Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes

• Published in: Biochimica et biophysica acta Vol. 1637; no. 1; pp. 98 - 106
• Main Authors: Beisswenger, Paul J, Howell, Scott K, Smith, Kenneth, Szwergold, Benjamin S
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 20.01.2003
• Subjects: Adult; Carbohydrate metabolism; Cells, Cultured; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - metabolism; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - metabolism; Enzyme Inhibitors - therapeutic use; Erythrocytes - drug effects; Erythrocytes - metabolism; Female; Glyceraldehyde-3-phosphate dehydrogenase; Glyceraldehyde-3-Phosphate Dehydrogenases - antagonists & inhibitors; Glyceraldehyde-3-Phosphate Dehydrogenases - metabolism; Humans; Hydrogen-Ion Concentration; Male; Methylglyoxal; Middle Aged; Oxidation-Reduction; Pyruvaldehyde - blood; Pyruvaldehyde - metabolism; Red blood cell; Sesquiterpenes - therapeutic use; Red blood cell; Methylglyoxal; Glyceraldehyde-3-phosphate dehydrogenase; Carbohydrate metabolism; Diabetes
• ISSN: 0925-4439; 0006-3002; 1879-260X
• DOI: 10.1016/S09254439(02)00219-3

Methylglyoxal (MG) may be an important cause of diabetic complications. Its primary source is dihydroxyacetone phosphate (DHAP) whose levels are partially controlled by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Using a human red blood cell (RBC) culture, we examined the effect of modifying GAPDH activity on MG production. With the inhibitor koningic acid (KA), we showed a linear, concentration-dependent GAPDH inhibition, with 5 μM KA leading to a 79% reduction of GAPDH activity and a sixfold increase in MG. Changes in redox state produced by elevated pH also resulted in a 2.4-fold increase in MG production at pH 7.5 and a 13.4-fold increase at pH 7.8. We found substantial inter-individual variation in DHAP and MG levels and an inverse relationship between GAPDH activity and MG production ( R=0.57, P=0.005) in type 2 diabetes. A similar relationship between GAPDH activity and MG was observed in vivo in type 1 diabetes ( R=0.29, P=0.0018). Widely varying rates of progression of diabetic complications are seen among individuals. We postulate that modification of GAPDH by environmental factors or genetic dysregulation and the resultant differences in MG production could at least partially account for this observation.